Why Are Check-Cap Shares Plummeting Today?

Following an internal assessment of the clinical data collected from calibration studies, Check-Cap Ltd (NASDAQ: check) said the current efficacy results don’t meet the goal to proceed to the powered portion of the US pivotal study.
The company initiated the first part of the pivotal US study of C-Scan in May 2022, focusing on device calibration and enhancement of C-Scan algorithms among the average-risk US population.
Check-Cap said the calibration studies’ target is to optimize the C-Scan device for the average risk population before commencing the powered portion of the US pivotal study, which aims to demonstrate C-Scan performance in a statistically significant manner.
The initiation of the powered portion of the US pivotal study was dependent upon the successful completion of the calibration portion of the US pivotal study.
The initiation of the powered portion of the US pivotal study that was expected in mid-2023 is therefore temporarily postponed.
The company will conduct additional clinical data analysis and approach the FDA to make amendments to the US pivotal study protocol that are expected to be part of an IDE supplement submission to the FDA.
The company plans to continue conducting its calibration studies, albeit slower, to collect additional clinical data. It is also implementing a cost reduction plan to extend its cash runway.
Price Action: CHEK shares are down 44.10% at $1.69 at the last check Tuesday.

How To Blogspot